globenewswire.com
Axogen Announces Pricing of Upsized $124 Million Public Offering of Common Stock
ALACHUA, Fla. and TAMPA, Fla.
AxoGen, Inc.AXGNNASDAQ
LOADING
|||
Latest News
Loading news...
globenewswire.com
Axogen Announces Proposed Public Offering of Common Stock
ALACHUA, Fla. and TAMPA, Fla.
seekingalpha.com
Axogen, Inc. (AXGN) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Axogen, Inc. (AXGN) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
fool.com
Axogen CEO Axed 25,000 Shares From His Direct Holdings
Axogen's CEO sold 25,000 shares directly for $750,000 on Dec. 10, 2025. The sale represented 28.24% of the CEO's direct holdings prior to the transaction, reducing direct ownership to 63,537 shares (approximately 0.14% of shares outstanding).
globenewswire.com
Axogen, Inc. Reports Preliminary Unaudited Revenue for Fourth Quarter and Full-Year 2025
ALACHUA, Fla. and TAMPA, Fla., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for the restoration of peripheral nerve function, today announced preliminary unaudited fourth quarter and full-year 2025 key financials.
defenseworld.net
Assenagon Asset Management S.A. Grows Stake in AxoGen, Inc. $AXGN
Assenagon Asset Management S.A. grew its stake in shares of AxoGen, Inc. (NASDAQ: AXGN) by 26.0% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 1,289,072 shares of the medical equipment provider's stock after purchasing an additional 265,950
globenewswire.com
Axogen Announces FDA Approval of Biologics License Application for AVANCE® (acellular nerve allograft–arwx)
ALACHUA, Fla. and TAMPA, Fla., Dec. 03, 2025 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical technologies for the restoration of peripheral nerve function, today announced that the U.S. Food and Drug Administration (the “FDA”) has approved the Biologics License Application (“BLA”) for AVANCE® (acellular nerve allograft-arwx).
reuters.com
FDA approves Axogen's nerve repair graft
The U.S. Food and Drug Administration has approved Axogen's nerve repair graft, the health regulator said on Wednesday.
seekingalpha.com
Avance Nerve Graft FDA Verdict Approaches, Why Investors Are Watching Axogen
Axogen, Inc. delivered strong Q3 '25 results, with revenue up 23.7% and a return to profitability, fueling bullish momentum. Surgeon adoption is accelerating ahead of the December 5th FDA decision on Avance Nerve Graft, a pivotal regulatory inflection point. The BLA submission features over a decade of real-world outcomes, robust manufacturing validation, and clinical recovery rates in the low-80% range.
seekingalpha.com
Wasatch Micro Cap Value Fund Q3 2025 Contributors And Detractors
The strongest contributor to Wasatch Micro Cap Value Fund performance for the quarter was Bel Fuse, Inc. Axogen, Inc. (AXGN) was also a top contributor, providing surgical solutions for peripheral nerve repair. The greatest detractor from Fund performance for the quarter was Limbach Holdings, Inc. (LMB).
seekingalpha.com
Axogen, Inc. (AXGN) Q3 2025 Earnings Call Transcript
Axogen, Inc. ( AXGN ) Q3 2025 Earnings Call October 29, 2025 8:00 AM EDT Company Participants Michael Dale - President, CEO & Director Lindsey Hartley - Chief Financial Officer Rick Ditto Jens Schroeder Kemp - Chief Marketing Officer Conference Call Participants Christopher Pasquale - Nephron Research LLC Michael Sarcone - Jefferies LLC, Research Division Caitlin Cronin - Canaccord Genuity Corp., Research Division Jayson Bedford - Raymond James & Associates, Inc., Research Division Michael Kratky - Leerink Partners LLC, Research Division Ross Osborn - Cantor Fitzgerald & Co., Research Division David Turkaly - Citizens JMP Securities, LLC, Research Division Frank Takkinen - Lake Street Capital Markets, LLC, Research Division Anthony Petrone Yi Chen - H.C. Wainwright & Co, LLC, Research Division Presentation Operator Good morning.
zacks.com
AxoGen (AXGN) Q3 Earnings and Revenues Top Estimates
AxoGen (AXGN) came out with quarterly earnings of $0.12 per share, beating the Zacks Consensus Estimate of $0.09 per share. This compares to earnings of $0.07 per share a year ago.
globenewswire.com
Axogen, Inc. Reports Third Quarter 2025 Financial Results
Raises Full Year Revenue Guidance to at Least 19% Growth or $222.8 million Raises Full Year Revenue Guidance to at Least 19% Growth or $222.8 million
prnewswire.com
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Axogen, Inc. - AXGN
NEW YORK , Oct. 18, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Axogen, Inc. ("Axogen" or the "Company") (NASDAQ: AXGN). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
prnewswire.com
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Axogen, Inc. - AXGN
NEW YORK , Oct. 13, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Axogen, Inc. ("Axogen" or the "Company") (NASDAQ: AXGN). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
prnewswire.com
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Axogen, Inc. - AXGN
NEW YORK , Oct. 8, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Axogen, Inc. ("Axogen" or the "Company") (NASDAQ: AXGN). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
prnewswire.com
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Axogen, Inc. - AXGN
NEW YORK , Oct. 3, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Axogen, Inc. ("Axogen" or the "Company") (NASDAQ: AXGN). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
businesswire.com
Axogen, Inc. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights – AXGN
LOS ANGELES--(BUSINESS WIRE)--Axogen, Inc. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights – AXGN.
businesswire.com
AXGN Investors Have Opportunity to Join Axogen, Inc. Fraud Investigation with the Schall Law Firm
LOS ANGELES--(BUSINESS WIRE)---- $AXGN--AXGN Investors Have Opportunity to Join Axogen, Inc. Fraud Investigation with the Schall Law Firm.
prnewswire.com
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Axogen, Inc. - AXGN
NEW YORK , Sept. 28, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Axogen, Inc. ("Axogen" or the "Company") (NASDAQ: AXGN).